摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-phenyl-[1,2,4,5]tetrazine | 36022-11-4

中文名称
——
中文别名
——
英文名称
3-phenyl-[1,2,4,5]tetrazine
英文别名
3-phenyl-1,2,4,5-tetrazine;3-phenyltetrazine;phenyl-[1,2,4,5]tetrazine;Phenyl-[1,2,4,5]tetrazin
3-phenyl-[1,2,4,5]tetrazine化学式
CAS
36022-11-4
化学式
C8H6N4
mdl
——
分子量
158.162
InChiKey
BDOSMWXSWHOGDF-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.3
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    51.6
  • 氢给体数:
    0
  • 氢受体数:
    4

SDS

SDS:c4a013d17a6187fe8c945313af122696
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Boron Trifluoride-Mediated Cycloaddition of 3-Bromotetrazine and Silyl Enol Ethers: Synthesis of 3-Bromo-pyridazines
    作者:Simon D. Schnell、Jorge A. González、Jan Sklyaruk、Anthony Linden、Karl Gademann
    DOI:10.1021/acs.joc.1c01384
    日期:2021.9.3
    regiocontrol remains difficult. We achieved the Lewis acid-mediated inverse electron demand Diels–Alder reaction between 3-monosubstituted s-tetrazine and silyl enol ethers and obtained functionalized pyridazines. In the case of 1-monosubstituted silyl enol ethers, exclusive regioselectivity was observed. Downstream functionalization of the resulting 3-bromo-pyridazines was demonstrated utilizing several cross-coupling
    哒嗪是药物化学或作物保护剂的重要支架,但选择性制备具有高区域控制的 3-溴哒嗪仍然很困难。我们实现了 3-单取代s-四嗪和甲硅烷基烯醇醚之间的路易斯酸介导的逆电子需求 Diels-Alder 反应,并获得了功能化的哒嗪。在 1-单取代的甲硅烷基烯醇醚的情况下,观察到排他性区域选择性。所得 3-溴-哒嗪的下游功能化利用几种交叉偶联方案来合成 3,4-二取代哒嗪,并能很好地控制取代模式。
  • BIO-ORTHOGONAL DRUG ACTIVATION
    申请人:KONINKLIJKE PHILIPS N.V.
    公开号:US20160106859A1
    公开(公告)日:2016-04-21
    The invention relates to a Prodrug activation method, for therapeutics, wherein use is made of abiotic reactive chemical groups that exhibit bio-orthogonal reactivity towards each other. The invention also relates to a Prodrug kit comprising at least one Prodrug and at least one Activator, wherein the Prodrug comprises a Drug and a first Bio-orthogonal Reactive Group (the Trigger), and wherein the Activator comprises a second Bio-orthogonal Reactive Group. The invention also relates to targeted therapeutics used in the above-mentioned method and kit. The invention particularly pertains to antibody-drug conjugates and to bi- and trispecific antibody derivatives.
    该发明涉及一种用于治疗学的原药激活方法,其中使用了表现出彼此生物正交反应性的非生物活性化学基团。该发明还涉及一种包含至少一种原药和至少一种激活剂的试剂盒,其中原药包含药物和第一个生物正交反应基团(触发器),而激活剂包含第二个生物正交反应基团。该发明还涉及在上述方法和试剂盒中使用的靶向治疗剂。该发明特别适用于抗体药物偶联物和双特异性及三特异性抗体衍生物。
  • Nucleophilic Attack on Nitrogen in Tetrazines by Silyl-Enol Ethers
    作者:Simon D. Schnell、Mauro Schilling、Jan Sklyaruk、Anthony Linden、Sandra Luber、Karl Gademann
    DOI:10.1021/acs.orglett.0c04113
    日期:2021.4.2
    The nucleophilic addition of silyl-enol ethers to nitrogen in 3-monosubstituted s-tetrazines mediated by BF3 is reported. The preference for this azaphilic addition over the usually observed inverse electron demand Diels–Alder reactions was evaluated theoretically and corroborated by experiments. The substrate dependency of this unusual reaction was rationalized by determination of the activation barriers
    报道了在BF 3介导的3-单取代的s-四嗪中氮上甲硅烷基烯醇醚的亲核加成反应。从理论上评估并通过实验证实了这种亲氮添加相对于通常观察到的逆电子需求Diels-Alder反应的偏爱。通过确定激活壁垒,并通过使用密度泛函理论在激活应变模型的基础上,合理化了这种异常反应的底物依赖性。
  • [EN] CHANNEL PROTEIN ACTIVATABLE LIPOSOMES<br/>[FR] LIPOSOMES ACTIVABLES PAR DES PROTÉINES DE CANAL
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081300A1
    公开(公告)日:2014-05-30
    Disclosed is a liposome, comprising a lipid bilayer enclosing a cavity, wherein the bilayer comprises a channel protein releasably linked to an eight-membered non-aromatic cyclic alkenylene group, preferably a cyclooctene group, and more preferably a trans-cyclooctene group. The liposomes are used in a kit comprising the liposome, the liposomal membrane of which comprises a channel protein linked to a Trigger, and an Activator for the Trigger, wherein the Trigger comprises the eight- membered non-aromatic cyclic alkenylene group, and the Activator comprises a diene.
    揭示了一种脂质体,包括包裹腔的脂质双层,其中双层包括与八元非芳香环烯链基(优选为环辛烯基,更优选为反式环辛烯基)可释放地连接的通道蛋白。这些脂质体用于一种套装,包括该脂质体,其脂质体膜包括连接到触发器的通道蛋白,以及用于触发器的激活剂,其中触发器包括八元非芳香环烯链基,而激活剂包括二烯。
  • [EN] CHEMICALLY CLEAVABLE GROUP<br/>[FR] GROUPE CLIVABLE PAR VOIE CHIMIQUE
    申请人:TAGWORKS PHARMACEUTICALS B V
    公开号:WO2014081303A1
    公开(公告)日:2014-05-30
    Disclosed is the use of the reactive components of the inverse electron-demand Diels Alder reaction for chemical masking and unmasking in vitro. This can be applied in complex chemical reactions and, particularly in the synthesis of biomolecules, e.g. on solid supports. The reactice components are a dienophile, particularly a trans-cyclooctene, and a diene, particularly a tetrazine.
    本文揭示了逆电子需求Diels-Alder反应的反应性组分用于体外化学掩蔽和解除掩蔽。这可以应用于复杂的化学反应中,特别是在生物分子合成中,例如在固相支持上。反应性组分包括双烯,特别是反式环辛二烯,和二烯,特别是四氮唑。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
cnmr
查看更多图谱数据,请前往“摩熵化学”平台
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台

同类化合物

酸四嗪 甲四嗪-氨基叔丁酯 四嗪-氨基叔丁酯 嘧啶并[4,5-e]-1,2,3,4-四嗪 二甲基-1,2,4,5-四嗪 二氯均四嗪 METHYLTETRAZINE-ACID,甲基四嗪-羧基 6-苯基-1,2,4,5-四嗪-3-胺 6-乙基-1,2,4,5-四嗪-3-胺 6-丁基氨基-3-(3,5-二甲基吡唑-1-基)四嗪 6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-胺 3,6-二苯基-1,2,4,5-四嗪 3,6-二氨基-1,2-二氢-1,2,4,5-四嗪盐酸盐 3,6-二-4-吡啶基-1,2,4,5-四嗪 3,6-二-2-吡啶基-1,2,4,5-四嗪 3,6-二(噻吩-2-基)-1,2,4,5-四嗪 3,6-二(3-吡啶基)-1,2,4,5-四氮杂苯 3,6-二(3,5-二甲基-1H-吡唑-1-基)-1,2,4,5-四嗪 1-[6-(3,5-二甲基吡唑-1-基)-1,2,4,5-四嗪-3-基]-2-(丙-2-亚基)肼 1,2-二氢-1,2,4,5-四嗪-3,6-二酮 1,2,4,5]四嗪-3,6-二羧酸 1,2,4,5-四嗪-3-胺 1,2,4,5-四嗪-3,6-二羧酸二甲酯 1,2,4,5-四嗪 (9CI)-吡咯并[2,1-d]-1,2,3,5-四嗪 (6-肼基-1,2,4,5-四嗪-3-基)肼 3-(3,5-Dimethyl-1-pyrazolyl)-6-(2-trifluoroacetylhydrazino)-1,2,4,5-tetrazine 3-cyclohexyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-ethyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 6-pentyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-benzyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine 3-methyl-6-(3,5-dimethyl-1H-pyrazol-1-yl)[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine N'-(6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-yl)propionohydrazide 3-(2-ethylidenehydrazinyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazine (1,2,4,5-tetrazine-3,6-diyl)dimethanol 3-amino-6-chloro-1,2,4,5-tetrazine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-methyl-1,2,4,5-tetrazin-3-amine N-(tert-butyl)-6-(3,5-dimethyl-1H-pyrazol-1-yl)-1,2,4,5-tetrazin-3-amine 6-(3,5-dimethyl-1H-pyrazol-1-yl)-N-(prop-2-en-1-yl)-1,2,4,5-tetrazin-3-amine 3-(2-pyrimidyl)-6-(2-hydroxy)ethyl-1,2,4,5-tetrazine 3-isopropyl-6-phenyl-1,2,4,5-tetrazine 6-butylamino-3-chlorotetrazine 3,6-di(1H-pyrazol-4-yl)-1,2,4,5-tetrazine N-(1H-tetrazol-5-yl)-1,2,4,5-tetrazin-3-amine 3-(3,5-dimethylpyrazolyl)-6-[tris(hydroxylmethyl)aminomethane]-1,2,4,5-tetrazine 2-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-ylamino)-2-(hydroxymethyl)propane-1,3-diol 6-amino-1,2,4-triazolo<4,3-b><1,2,4,5>tetrazine N-phenethyl-[1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-3-amine 2,5-dioxopyrrolidin-1-yl 2-(4-(6-methyl-1,2,4,5-tetrazin-3-yl)phenyl)acetate furazano-1,2,3,4-tetrazine 1,3-dioxide